Analyst Group Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051, valid until 2039. The granting of a patent covering the Japanese market is a significant milestone for Reponex, which has now obtained patent protection for the RNX-051 treatment method in both Europe and Japan – two of the Company's primary focus markets. Patent protection is seen as a key value driver and a crucial parameter in the future negotiations on the conditions for a potential license agreement.

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-pharma-equity-groups-obtained-patent-protection-in-japan-for-rnx-051/